BCG vaccine of 2004 the vaccine is given to about 100 million children per year globally. The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials conducted in the UK have consistently shown a protective effect of 60 to 80%, but those conducted elsewhere have shown no protective effect, and efficacy appears
BCG disease outbreak in Finland in the 2000s been crimes committed relating to use of the BCG vaccine. BCG disease outbreak in Finland in the 2000s BCG disease is an adverse effect of the Bacillus Calmette-Guérin vaccine. The vaccine contains living "Mycobacterium bovis" BCG, and in BCG disease, the bacterium causes a disease in persons vaccinated. Between 2000 and 2006, several hundred children in Finland had serious adverse events from the vaccine, including osteitis and osteomyelitis, disseminated (usually fatal) BCG infection, arthritis, and lymph node abscesses. Four deaths were registered in the official adverse event register, and while in only two cases a clear causal link was considered